SNA-001, a recombinant rhTSH drug candidate, can elevate the serum TSH level safely and fast. It is used for preparation for radioactive iodine remnant ablation and follow-up monitoring without the need for thyroid hormone withdrawal and symptomatic hypothyroidism in patients diagnosed with well-differentiated thyroid cancer. Based on solid clinical evidence, clinical guidelines of both China and U.S. strongly recommend rhTSH to be used as an alternative to thyroid hormone withdrawal in the treatment of differentiated thyroid cancer.
About 100 thousand new cases of thyroid cancer occur in China every year, recognized as one of the most rapidly increasing cancer site. Nonetheless, there is not any approved rhTSH products available for clinical use in Mainland China. Likely to become the first rhTSH product of Mainland China, SNA-001 is expected to generate huge economic returns and social benefits.
Founded in 2015 in Suzhou Industrial Park by Dr. Ting Xu of Suzhou Alphamab, SmartNuclide is a biopharmaceutical company focused on discovering and developing innovative biologics used in nuclear medicine, with its world-leading research and development technology platform for domain antibody-radiopharmaceuticals. Since inception, the company has raised several tens of millions RMB in two financing rounds from venture investors including Bohe Angel Fund, Watson Capital, Kington Capital, and Longmen Capital.